Alonso Krangle have filed a Bard IVC Filter lawsuit against C.R. Bard, Inc. and one of its subsidiaries, alleging that the defective design of its IVC (inferior vena cava) filter caused the plaintiff to suffer from serious internal injuries.
The product liability lawyers at Alonso Krangle have filed a Bard G2® IVC Filter lawsuit against C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. This Bard IVC Filter Lawsuit (case no. 2:13-cv-02281-LDW-AKT) was filed on April 16, 2013 in the U.S. District Court, Eastern District of New York. According to the complaint, this case alleges that Bard’s G2® Filter was defective and that these defects caused the device’s components to break off inside of the plaintiff, causing her to sustain severe and some permanent internal injuries. Additionally, this product liability lawsuit contends that Bard was aware of the dangers of the G2® Filter and, nevertheless, marketed this device as safe and effective without providing any warning about its potential dangers to the public.
Alonso Krangle’s experienced medical device and product liability attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous devices. We offer free evaluations to those who have sustained serious injuries that could be linked to Bard’s IVC Filters. To discuss a potential claim with one of the compassionate lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com
Bard IVC Filter lawsuit
According to court documents, the plaintiff underwent surgery in May 2009 to have the Bard G2® Filter implanted to treat her blood clots and prevent possible pulmonary embolism. The Bard G2® Filter is the second generation of the Bard Recovery® Filter, both of which are spider-like devices intended to stop or catch blood clots that may be passing through the inferior vena cava (IVC, one of the body’s major veins); these filter devices are typically only implanted in patients who are unable to take anticoagulant medications or who have had no success in reducing blood clots after taking these medications.
The Bard IVC Filter lawsuit goes on to explain that, following implantation of the G2® Filter, the filter failed, with its components breaking off, perforating the plaintiff’s IVC and migrating to other parts of her body. As a result of the G2® Filter failure, the plaintiff sustained serious injuries and damage to her internal organs. The failure of the Bard G2® Filter has reportedly caused the plaintiff to incur significant medical expenses and to have endured disabilities, mental anguish and excessive physical pain and suffering, all of which have negatively impacted her quality of life.
Study Reports High Failure Rate for Bard G2 IVC Filters
Although Bard has marketed its IVC filters as safe and effective at preventing pulmonary embolism, some studies have demonstrated that these filters are prone to an unreasonably high risk of failure and patient injury following implantation. In fact, a study published in the August 2010 Archives of Internal Medicine found that the Bard G2® IVC Filter had a failure rate of approximately 12 percent. This study also found that the Bard Recovery Filter, the G2® Filter’s predecessor, had a failure and fracture rate of about 25 percent. [http://www.ncbi.nlm.nih.gov/pubmed/20696949] As the results of this study were made public, in 2010, the FDA also issued a public warning regarding the risk of adverse events when using IVC filters. [http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm221707.htm]
Given the results of this and similar studies, coupled with the fact that Bard failed to conduct any clinical testing on its IVC filters to evaluate their safety and efficacy, the complaint alleges that Bard knew or should have known that the G2® Filter was defective and unreasonably dangerous and, consequently, should have warned the public about these potential dangers.
About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.